KROS News and Press, Keros Therapeutics Inc. From 12/13/21

Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Trea...

Keros Therapeutics (NASDAQ:KROS) has entered into a licensing agreement with Hansoh (Shanghai) Healthtech Company, a subsidiary of Hansoh Pharmaceutical Group in China. Under the terms of the agreement, Hansoh will obtain an exclusive license from Keros to develop, manufacture and commerciali...

Keros Therapeutics will be hosting a conference call and webcast today, December 13, 2021, at 4:01 p.m. ET. LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus...

Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Ke...

LEXINGTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Syndax Pharmaceuticals (SNDX -16.0%) has dropped over 10% after the company shared updated data from a Phase 1/2 trial for SNDX-5613 in patients with mutant relapsed/refractory (R/R) acute leukemias. In the AUGMENT-101 trial that included patients with MLLr and NPM1c mutation, the composite c...

Keros Therapeutics (KROS +26.1%) has reached a four-month high after the company highlighted an abstract posted on the website of the American Society of Hematology (“ASH”) indicating data from a Phase 2 trial for its lead protein candidate KER-050 in myelodysplastic Syndro...

Keros Therapeutics (NASDAQ:KROS): Q3 GAAP EPS of -$0.87 misses by $0.15. Cash and cash equivalents of $221.35M. Press Release For further details see: Keros Therapeutics EPS misses by $0.15